NCT02082808 - Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

DTG

DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side

DRUG

DCV

DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet

Trial Locations (1)

GSK Investigational Site, Overland Park